An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins.
While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed.
At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class small molecule programs targeted at classically undruggable proteins and non-coding RNA targets, targeting both human and non-human biology.
Company Details
Serna Bio Questions
Serna Bio's LinkedIn profile is https://www.linkedin.com/company/sernabio
Serna Bio has
15 employees.
View email and phone details for 15
employees at Serna Bio.
Serna Bio's industry is
Biotechnology Research
Serna Bio's top competitors are
Benevolentai,
Kerna Labs,
Deepseq.ai,
Deciduous Therapeutics,
Aikium Inc.,
Arda Therapeutics,
Birdwood Therapeutics,
Sensyne Health,
Encepheal Therapeutics,
Leash Bio.
Serna Bio's categories are Biotechnology Research
Serna Bio's founding year is 2021
